Page 6 - Dr Reddy's Laboratories
Dr Reddy's consolidated net dips 28% to Rs 554 crore in March quarter
Dr Reddy's Laboratories on Friday reported a consolidated net profit of Rs 554 crore for the quarter ended March, down 28 per cent from Rs 764 crore in the same period of the previous fiscal.The company said selling, general and administrative (SG & A) expenses went up by 17 per cent to Rs 1,430 crore due to incremental costs after the integration of Wockhardt's acquired divisions and increased freight expenses.Consolidated revenues grew 7 per cent year-on-year to Rs 4,728 crore while R & D expenses comprised 8.7 per cent of revenues at Rs 409 crore.Earnings before interest, taxes, depreciation and amortisation (EBITDA) were up 13 per cent year-on-year during Q4 FY21 at Rs 1,133 crore.For the entire year (FY21), profit after tax totalled Rs 1,915 crore on revenues of Rs 18,972 crore.Co-Chairman and MD G V Prasad said the company continued to grow across all businesses, enhanced productivity and strengthened development pipeline."We are prioritising our efforts to launch ...
 "Dr Reddy's consolidated net dips 28% to Rs 554 crore in March quarter")
Covid-19: Govt waives import duty on Remdesivir injection, raw materials
Given the shortage of supplies, the Union government last week banned the export of Remdesivir
 "Covid-19: Govt waives import duty on Remdesivir injection, raw materials")
Dr Reddy's to also use govt cold chain infra for Sputnik V distribution
The vaccine would be transported in frozen form by air and road
 "Dr Reddy's to also use govt cold chain infra for Sputnik V distribution")
Dr Reddy's stock sheds 4% as Sputnik V pricing, competition weigh
Access to the private market, international sales are other factors that will impact margins
 "Dr Reddy's stock sheds 4% as Sputnik V pricing, competition weigh")
India gets third Covid-19 vaccine as SEC clears Russia's Sputnik V
Final nod from DCGI soon, jab likely at $3/dose
Dr Reddys surges 5% as Sputnik V gets expert panel nod for emergency use
This is the third vaccine approved by India, after Covishield and Covaxin.
 "Dr Reddys surges 5% as Sputnik V gets expert panel nod for emergency use")
India drug regulator asks Dr. Reddy's for more data on Sputnik V vaccine
An expert panel of India's drug regulator sought additional data from drugmaker Dr Reddy's on its Sputnik V Covid-19 vaccine trial, in its second such request after an initial evaluation in February
Expert panel defers decision on Sputnik V Covid-19 vaccine, wants more data
Details of -25°C cold chain plan sought
No Sputnik V approval yet, SEC asks Dr Reddy's for more data on vax
The Subject Expert Committee (SEC) of the Indian drug regulator, tasked with vetting Covid-19 vaccine proposals, sought additional data on Russian Covid-19 vaccine 'Sputnik V'
Wait for Sputnik V Covid-19 vaccine may get over in a few weeks: DRL
"We expect to get the approval in the next few weeks," said Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL)
Dr Reddy's expects Covid vaccine to get nod from India in next few weeks
Pharma major Dr Reddy's Laboratories expects the Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks, a company official has said
 "Dr Reddy's expects Covid vaccine to get nod from India in next few weeks")
Stelis Biopharma to make 200 mn doses of Russia's Sputnik V Covid vaccine
Stelis will commence supplies from September quarter of 2021 and will also continue to work with RDIF to provide additional supply volumes beyond the initial agreement
 "Stelis Biopharma to make 200 mn doses of Russia's Sputnik V Covid vaccine")
Dr Reddy's Lab receives 3 observations for New York API manufacturing plant
The pharma firm said it will address all observations comprehensively within the stipulated timeline
Decoded: How Covid-19 vaccine efficacy helps to get an idea of protection
Efficacy of a vaccine means its ability to stimulate immunity in a person who has received the shot
 "Decoded: How Covid-19 vaccine efficacy helps to get an idea of protection")
Expert panel asks DRL to come back with more data on Sputnik safety
DRL applied for restricted emergency use of Sputnik V last week, has lined up 250 mn doses for Indians over next 12 months
Dr Reddy's applies for emergency use approval for Sputnik V vaccine
Aims to launch the vaccine in March if regulator approval comes through
 "Dr Reddy's applies for emergency use approval for Sputnik V vaccine")
Lupin plans expansion, aims to enter Chinese market in the next one year
The company has now decided to focus on specialty drugs. The annual price cuts made the Japanese generics market unattractive
 "Lupin plans expansion, aims to enter Chinese market in the next one year")
Dr Reddy's reports Q3 profit of Rs 20 crore, revenues at Rs 4,930 crore
DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment.
Dr Reddy's Laboratories likely to launch Sputnik V under EUA in March
The bridge trials on 1,600 participants in India was ongoing. The phase 2 trials are completed and the phase 3 is on.
 "Dr Reddy's Laboratories likely to launch Sputnik V under EUA in March")
Dr Reddy's, Zuventus get nod to conduct Covid-19 trials on repurposed drugs
NeuroRx and Relief Therapeutics have partnered to develop a drug called RLF-100 that has anti-inflammatory and anti-cytokine activity properties.
 "Dr Reddy's, Zuventus get nod to conduct Covid-19 trials on repurposed drugs")
